Skip to main content

Advertisement

Log in

Ganciclovir-related neutropenia after preemptive therapy for cytomegalovirus infection: comparison between cord blood and bone marrow transplantation

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

We studied ganciclovir (GCV)-related neutropenia after preemptive therapy for cytomegalovirus infection: 9 of 17 (53%) cord blood transplantation (CBT) patients and 18 of 20 (90%) bone marrow transplantation (BMT) patients developed GCV-related neutropenia with an absolute neutrophil count (ANC) of less than 1000/μl. Among the patients who did not receive granulocyte colony-stimulating factor, 2 (13%) and 1 (7%) CBT patients, and 10 (56%) and 8 (44%) BMT patients, developed neutropenia with an ANC of less than 500 and 250/μl, respectively. The incidences of neutropenia in patients with an ANC of less than 1000, 500, and 250/μl were significantly lower after CBT in comparison with BMT. Two BMT patients, but no CBT patients, developed neutropenic fever, and both patients recovered after antibiotic therapy. In CBT patients, a creatinine clearance rate of less than 50 ml/min and an absence of steroid therapy were associated with a greater incidence of GCV-related neutropenia. No risk factors for GCV-related neutropenia were found in BMT patients. These results suggest that GCV may be less toxic to myeloid progenitor cells from cord blood than those from bone marrow.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Forman SJ, Zaia JA (1994) Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? Blood 83:2392–2398

    CAS  PubMed  Google Scholar 

  2. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD (1993) Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118:173–178

    Google Scholar 

  3. Boeckh M, Bowden RA, Gooley T, Myerson D, Corey L (1999) Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 93:1781–1782

    PubMed  Google Scholar 

  4. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M (1997) Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 90:2502–2508

    CAS  PubMed  Google Scholar 

  5. Tomonari A, Iseki T, Ooi J, Takahashi S, Shindo M, Ishii K, Nagamura F, Uchimaru K, Tani K, Tojo A, Asano S (2003) Cytomegalovirus infection following unrelated cord blood transplantation for adult patients: a single institute experience in Japan. Br J Haematol 121:304–311

    PubMed  Google Scholar 

  6. Snydman DR (1988) Ganciclovir therapy for cytomegalovirus disease associated with renal transplants. Rev Infect Dis 10 [Suppl 3]:S554–S562

    PubMed  Google Scholar 

  7. Sommadossi JP, Carlisle R (1987) Toxicity of 3′-azido-3′-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother 31:452–454

    CAS  PubMed  Google Scholar 

  8. Crumpacker CS (1996) Ganciclovir. N Engl J Med 335:721–729

    CAS  PubMed  Google Scholar 

  9. Holberg-Petersen M, Rollag H, Beck S, Overli I, Tjonnfjord G, Abrahamsen TG, Degre M, Hestdal K (1996) Direct growth suppression of myeloid bone marrow progenitor cells but not cord blood progenitors by human cytomegalovirus in vitro. Blood 88:2510–2516

    CAS  PubMed  Google Scholar 

  10. Sommadossi JP, Bevan R, Ling T, Lee F, Mastre B, Chaplin MD, Nerenberg C, Koretz S, Buhles WC, Sommadossi JP, Bevan R, Ling T, Lee F, Mastre B, Chaplin MD, Nerenberg C, Koretz S, Buhles WC (1988) Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev Infect Dis 10 [Suppl 3]:S507–S514

    PubMed  Google Scholar 

  11. Saavedra S, Sanz GF, Jarque I, Moscardo F, Jimenez C, Lorenzo I, Martin G, Martinez J, De la Rubia J, Andreu R, Molla S, Llopis I, Fernandez MJ, Salavert M, Acosta B, Gobernado M, Sanz MA (2002) Early infections in adult patients undergoing unrelated donor cord blood transplantation. Bone Marrow Transplant 30:937–943

    Article  CAS  PubMed  Google Scholar 

  12. Michel G, Rocha V, Chevret S, Arcese W, Chan KW, Filipovich A, Takahashi TA, Vowels M, Ortega J, Bordigoni P, Shaw PJ, Yaniv I, Machado A, Pimentel P, Fagioli F, Verdeguer A, Jouet JP, Diez B, Ferreira E, Pasquini R, Rosenthal J, Sievers E, Messina C, Iori AP, Garnier F, Ionescu I, Locatelli F, Gluckman E (2003) Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood 102:4290–4297

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Maki Monna-Oiwa for her secretarial assistance. We also thank the KOBAYASHI Foundation for financial support.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Akira Tomonari.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tomonari, A., Iseki, T., Takahashi, S. et al. Ganciclovir-related neutropenia after preemptive therapy for cytomegalovirus infection: comparison between cord blood and bone marrow transplantation. Ann Hematol 83, 573–577 (2004). https://doi.org/10.1007/s00277-004-0887-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-004-0887-2

Keywords

Navigation